The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that ...

The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

Studies show Zepbound can improve the condition by reducing ... Mounjaro to treat Type 2 diabetes and became popular as an off-label weight-loss treatment. Tirzepatide works by stimulating two ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with competitor Eli Lilly’s Zepbound.

Jan 14 (Reuters) - Eli Lilly's (LLY.N), opens new tab stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the ...

Eli Lilly’s expectations for sales in the fourth quarter of last year missed forecasts, driven by lower-than-expected sales of its diabetes and obesity drugs Mounjaro and Zepbound. This is ...

The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk ... heart failure in 2021 and secured an expanded label in a hard-to-treat population the next year.